Loading…

Acquired hemophilia A. A monocentric retrospective study of 39 patients

Acquired haemophilia A (AHA) is a rare bleeding disorder, due to the presence of an inhibitor directed against factor VIII (FVIII). About 50% of the AHA are idiopathic, while the remaining 50% are related to an underlying disorder or condition (autoimmune diseases, malignancies, postpartum, etc.). W...

Full description

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2013-01, Vol.34 (1), p.4-11
Main Authors: Graveleau, J, Trossaërt, M, Leux, C, Masseau, A, Ternisien, C, Néel, A, Fouassier, M, Agard, C, Sigaud, M, Hamidou, M
Format: Article
Language:fre
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acquired haemophilia A (AHA) is a rare bleeding disorder, due to the presence of an inhibitor directed against factor VIII (FVIII). About 50% of the AHA are idiopathic, while the remaining 50% are related to an underlying disorder or condition (autoimmune diseases, malignancies, postpartum, etc.). We report on a monocentric retrospective cohort of 39 patients with AHA. Data were collected and compared to recent published data. Thirty-nine patients were admitted for AHA between 1993 et 2011. Mean age at diagnosis was 71.3 years, and we noted a marked male predominance. Although the majority of patients presented a bleeding event at diagnosis (94.9%), the hemorrhagic mortality was low (2.6%). On the contrary, immunosuppressive morbidity and mortality were high in this elderly population. There was a clear correlation between initial FVIII inhibitor titer and complete remission delay. We did not identify prognostic factor for global survival. AHA is a rare but potentially fatal disorder. Rapidity of diagnosis and treatment initiation is crucial. Morbidity and mortality, particularly of infectious cause, due to immunosuppressive treatment, should lead to consider other available therapeutical options.
ISSN:1768-3122
DOI:10.1016/j.revmed.2012.10.367